SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

Rhea-AI Summary

Medtronic plc (MDT) announces positive results from the largest head-to-head TAVR trial, showing non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien at one year.

Positive

• Positive results from the largest head-to-head TAVR trial by Medtronic plc.
• Superior valve performance and non-inferior clinical outcomes for Evolut TAVR.
• SMART Trial demonstrates benefits of Evolut TAVR in patients with small aortic annuli.
• Significant findings for women with severe aortic stenosis, highlighting need for tailored treatment approaches.
• Evolut TAVR meets co-primary endpoints of non-inferiority and hemodynamic superiority at one year.

Negative

• None.

Cardiologist

From a clinical perspective, the SMART Trial's findings are pivotal for the management of symptomatic severe aortic stenosis in patients with small aortic annuli, a condition that predominantly affects women. The trial's emphasis on a demographic that is both underrepresented and more severely affected by AS underscores the importance of personalized healthcare. The non-inferiority in clinical outcomes coupled with the superior valve performance of the Evolut TAVR system could influence clinical decision-making, potentially leading to a preference for this device over the Sapien system in certain patient populations.

It's notable that the trial achieved a hemodynamic superiority endpoint, which is a measure of how well blood can flow through the new valve. This is particularly relevant as improper blood flow can lead to heart failure, necessitating rehospitalization, or even death. The substantial reduction in bioprosthetic valve dysfunction with the Evolut TAVR system suggests that patients could experience better long-term outcomes, which is important given the mortality risks associated with aortic stenosis.

Medical Device Analyst

The results of the SMART trial have significant implications for Medtronic's market positioning in the TAVR space. Demonstrating non-inferiority and superiority in valve performance relative to a competitor's product provides a competitive edge that could translate into increased market share and potentially justify a premium pricing model for the Evolut TAVR system. The data could also influence purchasing decisions by hospitals and treatment recommendations by physicians, leading to a higher adoption rate of Medtronic's device.

Investors should note that the trial's outcome may not only impact Medtronic's revenue in the short term but could also affect the company's research and development strategy. Continued investment in clinical trials that focus on underrepresented populations could further strengthen Medtronic's position as a leader in equity-focused healthcare innovation.

Health Equity Advocate

The SMART trial's focus on a patient population that is primarily women is commendable and a step forward in addressing health inequities. The fact that 87% of the trial's participants were women highlights an intentional effort to generate data that can improve treatment for a group that has historically been under-diagnosed and under-treated. This approach not only has the potential to enhance patient outcomes but also to drive systemic change in how clinical trials are designed and executed, ensuring they are more reflective of the real-world patient population.

Moreover, the trial's findings could be instrumental in advocating for more widespread and routine cardiac assessments for women over 65, who are at increased risk for chronic conditions associated with aortic stenosis. This could lead to earlier interventions and better management of the condition, ultimately improving the quality of life and survival rates for this demographic.

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine. The one-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut™ TAVR platform compared to the SAPIEN™ platform.

"SMART was launched to better understand how the two most commonly used TAVR systems perform in patients with small aortic annuli, and particularly in women who tend to have smaller heart valves," said Nina Goodheart, senior vice president and president, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. "We continue to develop evidence to better understand the benefits of our Evolut TAVR technology in all patients, including patient populations that are underrepresented, under-diagnosed and under-treated. The results from the SMART trial demonstrate these benefits in a large patient population and reinforce our commitment to driving health equity and engineering the best technology to solve unmet patient needs."

In addition to being the largest comparative trial of TAVR, SMART is also the largest TAVR trial to date to enroll primarily women (87%). Symptomatic severe aortic stenosis can be fatal if left untreated and the average patient survival is two years without treatment.¹ Despite women's longer life expectancy, once impacted by severe aortic stenosis they suffer from higher mortality than men, even after matching for age.² Both TAVR and surgical aortic valve replacement (SAVR) are options for women to treat AS. Due to their smaller aortic annuli, women can often receive a valve replacement that does not properly fit their anatomy — highlighting the need for clinical evidence to inform the best treatment approaches.³ Additionally, despite prevalence of chronic conditions associated with AS in women over 65, a new survey of over 1,000 women announced today found that the majority have never been referred to a cardiologist. 

"As clinicians, we know that tailored approaches are needed to address the unique presentation of AS in the small annulus patient population, which is primarily women. Little comparative data exists to help us with valve selection," said Howard C. Herrmann, M.D., Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Penn., and lead investigator of the SMART Trial. "While we know women have a greater benefit than men when treated with TAVR vs SAVR, now for the first time there is definitive data demonstrating that women have the best valve performance when treated with the Evolut TAVR system."

The SMART Trial is an international, prospective, multi-center, randomized (1:1) post-market trial comparing the safety and performance of self-expanding versus balloon-expandable TAVR in patients with symptomatic severe AS and SAA. The trial randomized and treated 716 patients, 87% of which were women, across more than 80 sites worldwide. Eligible patients had a computed tomography aortic valve annulus area of ≤430 mm² and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ valve.

"For patients with heart valve replacements, early bioprosthetic valve dysfunction can lead to increased risk of serious long term outcomes including mortality and rehospitalization," added Dr. Herrmann. "As clinicians, these data further reinforces that not all valves are the same, and we strongly need to consider valve performance when determining device selection."

Results demonstrated that the Evolut TAVR platform met both co-primary endpoints of clinical non-inferiority and hemodynamic superiority at one year.

• Evolut TAVR met non-inferiority for the clinical outcome primary endpoint, a composite of all-cause mortality, disabling stroke, or heart failure rehospitalization at one year (9.4% Evolut vs. 10.6% SAPIEN, p<0.001 for non-inferiority).
• Evolut TAVR demonstrated superiority for the valve function primary endpoint, bioprosthetic valve dysfunction through one year (9.4% Evolut vs. 41.6% SAPIEN, p<0.001 for superiority).

"Medtronic is committed to providing clinicians and patients with aortic stenosis long-term data to help to inform their treatment decisions," said Jeffrey Popma, M.D., vice president and Chief Medical Officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business at Medtronic. "Our prior studies have shown an important link between valve performance, mortality, and re-hospitalization at five years. All SMART patients will be followed for five years to assess the relationship between better valve performance and improved clinical outcomes in patients with small annuli."

Analyst and Investor Briefing 

Medtronic will host an analyst and investor briefing to discuss the results from the SMART Trial on Sunday, April 7, 2024, at 10:45 AM EDT. The briefing will feature remarks from Medtronic management, immediately followed by answering questions from institutional investors and equity analysts. A live, listen-only webcast will be available and can be accessed by clicking on the Events link at investorrelations.medtronic.com on April 7. An archived replay will be available on the same webpage later in the day. This event is not part of the official ACC Scientific Sessions.  

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com, and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation.

¹Carabello BA, Paulus WJ. Aortic stenosis. Lancet. March 14, 2009;373(9667):956-966.

²Am Heart Assoc. 2021;10:e018816. DOI: 10.1161/JAHA.120.018816.

³Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of progression of aortic stenosis. Chest. April 1998;113(4):1109-1114

Contact: 
Ryan Weispfenning 
Investor Relations 
+1-763-505-4626 
 
Kimberly Powell 
Public Relations 
+1-202-498-2601 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/smart-trial-one-year-data-demonstrates-medtronic-evolut-tavr-platform-as-optimal-treatment-for-severe-aortic-stenosis-in-patients-with-small-annulus-which-is-primarily-women-302109869.html

SOURCE Medtronic plc

What are the key findings from the SMART Trial by Medtronic plc?

The trial showed non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien at one year.

Who presented the new data from the SMART Trial?

The data were presented at the American College of Cardiology Annual Scientific Session and published in The New England Journal of Medicine.

What is the ticker symbol for Medtronic plc?

The ticker symbol is MDT.

What is the SMART Trial about?

It is a head-to-head comparative trial of TAVR systems in patients with small aortic annuli.

What percentage of patients in the SMART Trial were women?

87% of patients were women.

What are the primary endpoints met by the Evolut TAVR platform?

Evolut TAVR met non-inferiority for clinical outcomes and demonstrated superiority for valve function at one year.

When will Medtronic host an analyst and investor briefing to discuss the SMART Trial results?

The briefing will take place on April 7, 2024, at 10:45 AM EDT.

Where can the webcast of the analyst and investor briefing be accessed?

The webcast can be accessed by clicking on the Events link at investorrelations.medtronic.com on April 7.

What is the importance of valve performance in TAVR procedures according to Dr. Herrmann?

Valve performance is crucial as it can impact long-term outcomes including mortality and rehospitalization.

What is the commitment of Medtronic regarding providing data for aortic stenosis treatment decisions?

Medtronic is committed to offering clinicians and patients with long-term data to inform treatment decisions for aortic stenosis.